Viking Therapeutics Advances Oral Weight-Loss Pill into Phase 3 Trials

Viking Therapeutics (VKTX) has officially initiated its SUNRISE Phase 3 registration program to evaluate the efficacy of a daily oral tablet version of VK2735, a dual GLP-1 and GIP receptor agonist. This move aims to provide patients with a convenient alternative to traditional weekly injections in the rapidly expanding obesity drug market. In addition to the oral trial progress, maintenance studies for the subcutaneous injection formulation demonstrated that patients could successfully maintain weight loss even when transitioning to biweekly or monthly dosing schedules. This flexibility offers a potential competitive advantage regarding patient compliance and treatment costs. To support these clinical advancements and prepare for future commercial manufacturing, Viking successfully raised $575 million through stock and convertible note offerings. This capital injection brings the company's total cash reserves to $960 million, providing a significant financial runway for its ongoing Phase 3 programs.

By The Motley Fool Team · Motley Fool ·

Viking Therapeutics Advances Oral Weight-Loss Pill into Phase 3 Trials

Tickers: $VKTX

Topics: clinical trials earnings report GLP-1 receptor agonists weight-loss drugs

Read the full article at Motley Fool

More Health news